Moxifloxacin punctum plug for sustained drug delivery

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 4, 2012, Pages 340-349

  Chee, Soon Phaik ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BACTERIAL CONJUNCTIVITIS; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LACRIMAL FLUID; MALE; MINIMUM INHIBITORY CONCENTRATION; PHASE 1 CLINICAL TRIAL; SLIT LAMP; SUSTAINED DRUG RELEASE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CATARACT; CATARACT EXTRACTION; CONJUNCTIVITIS, BACTERIAL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; ENDPOINT DETERMINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; QUINOLINES; TEARS; TIME FACTORS;

EID: 84864612748     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0162     Document Type: Article

References (54)

1. Patel, P.B., Diaz, M.C., Bennett, J.E., and Attia, M.W. Clinical features of bacterial conjunctivitis in children. Acad. Emerg. Med. 14:1-5, 2007.
2. Ohnsman, C., Ritterband, D., O'Brien, T., Girgis, D., and Kabat, A. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr. Med. Res. Opin. 23:2241-2249, 2007.
3. Mueller, J.B., and McStay, C.M. Ocular infection and inflammation. Emerg. Med. Clin. North Am. 26:57-72, vi, 2008.
4. Ohnsman, C.M. Exclusion of students with conjunctivitis from school: policies of state departments of health. J. Pediatr. Ophthalmol. Strabismus. 44:101-105, 2007.
5. Gigliotti, F., Hendley, J.O., Morgan, J., Michaels, R., Dickens, M., and Lohr, J. Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J. Pediatr. 104:623-626, 1984.
6. Taban, M., Behrens, A., Newcomb, R.L., et al. Acute endophthalmitis following cataract surgery: A systematic review of the literature. Arch. Ophthalmol. 123:613-620, 2005.
7. Chang, D.F., Braga-Mele, R., Mamalis, N., et al. Prophylaxis of postoperative endophthalmitis after cataract surgery: Results of the 2007 ASCRS member survey. J. Cataract Refract. Surg. 33:1801-1805, 2007.
8. Han, D.P., Wisniewski, S.R., Wilson, L.A., et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am. J. Ophthalmol. 122:1-17, 1996.
9. Vigamox [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2008.
10. Zymar [package insert]. Irvine, CA: Allergan, Inc.; 2010.
11. Asbell, P.A., Colby, K.A., Deng, S., et al. Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 145:951-958, 2008.
12. Wagner, R.S., Abelson, M.B., Shapiro, A., and Torkildsen, G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch. Ophthalmol. 123:1282-1283, 2005.
13. Stewart, W.C., Crean, C.S., Zink, R.C., Brubaker, K., Haque, R.M., and Hwang, D.G. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Am. J. Ophthalmol. 150:744-751.e2, 2010.
14. Holland, E.J., Lane, S.S., Kim, T., Raizman, M., and Dunn, S. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea. 27:314-319, 2008.
15. McCulley, J.P., Caudle, D., Aronowicz, J.D., and Shine, W.E. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 113:955-959, 2006.
16. Kim, D.H., Stark, W.J., O'Brien, T.P., and Dick, J.D. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 112:1992-1996, 2005.
17. Solomon, R., Donnenfeld, E.D., Perry, H.D., et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 112:466-469, 2005.
18. Katz, H.R., Masket, S., Lane, S.S., et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 24:955-958, 2005.
19. Hariprasad, S.M., Blinder, K.J., Shah, G.K., et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch. Ophthalmol. 123:39-44, 2005.
20. Silver, L.H., Woodside, A.M., and Montgomery, D.B. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv. Ophthalmol. 50 Suppl 1:S55-S63, 2005.
21. Pestova, E., Millichap, J.J., Noskin, G.A., and Peterson, L.R. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45:583-590, 2000.
22. Hwang, D.G. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv. Ophthalmol. 49 Suppl 2:S79-S83, 2004.
23. Fukuda, M., and Sasaki, H. Measurement of AQCmax of five different ophthalmic solutions and discussion of its new application. J. Ocul. Pharmacol. Ther. 25:351-356, 2009.
24. Yamada, M., Mochizuki, H., Yamada, K., Kawai, M., and Mashima, Y. Aqueous humor levels of topically applied levofloxacin in human eyes. Curr. Eye Res. 24:403-406, 2002.
25. Bauernfeind, A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651, 1997.
26. Kowalski, R.P., Yates, K.A., Romanowski, E.G., Karenchak, L.M., Mah, F.S., and Gordon, Y.J. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 112:1987, 2005.
27. Stroman, D.W., Dajcs, J.J., Cupp, G.A., and Schlech, B.A. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv. Ophthalmol. 50 Suppl 1:S16-S31, 2005.
28. Mather, R., Karenchak, L.M., Romanowski, E.G., and Kowalski, R.P. Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am. J. Ophthalmol. 133:463-466, 2002.
29. Wagner, R.S., Granet, D.B., Lichtenstein, S.J., et al. Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin. Clin. Ophthalmol. 4:41-45, 2010.
30. Smith, E.F., Elbash, A.R., Schrier, A., Berg, P.D., and Eid, I. Antimicrobial activity of acrylic intraocular lenses soaked in fourth generation fluoroquinolones. J. Ocul. Pharmacol. Ther. 24:495-500, 2008.
31. Aliprandis, E., Ciralsky, J., Lai, H., Herling, I., and Katz, H.R. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. Cornea. 24:201-205, 2005.
32. Balzli, C.L., McCormick, C.C., Caballero, A.R., et al. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin- resistant Staphylococcus aureus keratitis. J. Cataract Refract. Surg. 34:295-301, 2008.
33. Kowalski, R.P., Romanowski, E.G., Mah, F.S., Sasaki, H., Fukuda, M., and Gordon, Y.J. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinoloneresistant Staphylococcus aureus rabbit model. Jpn. J. Ophthalmol. 52:211-216, 2008.
34. Kowalski, R.P., Romanowski, E.G., Mah, F.S., Yates, K.A., and Gordon, Y.J. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am. J. Ophthalmol. 138:33-37, 2004.
35. Kowalski, R.P., Romanowski, E.G., Mah, F.S., Yates, K.A., and Gordon, Y.J. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am. J. Ophthalmol. 140:497-504, 2005.
36. Betanzos-Cabrera, G., Juarez-Verdayes, M.A., Gonzalez- Gonzalez, G., Cancino-Diaz, M.E., and Cancino-Diaz, J.C. Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis. Ophthalmic Res. 42:43-48, 2009.
37. Dridi, L., Tankovic, J., Burghoffer, B., Barbut, F., and Petit, J.C. gyrA and gyrB mutations are implicated in crossresistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 46:3418-3421, 2002.
38. Granet, D.B., Dorfman, M., Stroman, D., and Cockrum, P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J. Pediatr. Ophthalmol. Strabismus. 45:340-349, 2008.
39. Bassett, M., Blizzard, C., Mulani, D., Jarrett, P., and Sawhney, A. Pharmacokinetic profile of moxifloxacin in the tear fluid of canines delivered from a hydrogel punctum plug. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2011.
40. Zelenitsky, S.A., Ariano, R.E., Iacovides, H., Sun, S., and Harding, G.K. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J. Antimicrob. Chemother. 51:905-911, 2003.
41. Vigamox. Product monograph. Alcon Laboratories, Inc. 2004. Available at www.alcon.ca/alcon-products/Pharmaceutical .asp.
42. Mather, R., Stewart, J.M., Prabriputaloong, T., Wong, J., and McLeod, S.D. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am. J. Ophthalmol. 138:554-559, 2004.
43. Kleinmann, G., Larson, S., Hunter, B., Stevens, S., Mamalis, N., and Olson, R.J. Collagen shields as a drug delivery system for the fourth-generation fluoroquinolones. Ophthalmologica. 221:51-56, 2007.
44. Hariprasad, S.M., Mieler, W.E., Shah, G.K., et al. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans. Am. Ophthalmol. Soc. 102:149-155; discussion 155-147, 2004.
45. Hariprasad, S.M., Shah, G.K., Chi, J., and Prince, R.A. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J. Cataract Refract. Surg. 31:2142-2146, 2005.
46. Kowalski, R.P., Dhaliwal, D.K., Karenchak, L.M., et al. Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am. J. Ophthalmol. 136:500-505, 2003.
47. McGee, D.H., Holt, W.F., Kastner, P.R., and Rice, R.L. Safety of moxifloxacin as shown in animal and in vitro studies. Surv. Ophthalmol. 50 Suppl 1:S46-S54, 2005.
48. Ly, L.T., Cavanagh, H.D., and Petroll, W.M. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Eye Contact Lens. 32:161-165, 2006.
49. Donaldson, K.E., Marangon, F.B., Schatz, L., Venkatraman, A.S., and Alfonso, E.C. The effect of moxifloxacin on the normal human cornea. Curr. Med. Res. Opin. 22:2073-2080, 2006.
50. Granet, D., Lichtenstein, S.J., Onofrey, B., and Katz, J.A. An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite. Clin. Ophthalmol. 1:519-525, 2007.
51. Arbisser, L.B. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J. Cataract Refract. Surg. 34:1114-1120, 2008.
52. Lane, S.S., Osher, R.H., Masket, S., and Belani, S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J. Cataract Refract. Surg. 34:1451-1459, 2008.
53. Espiritu, C.R., Caparas, V.L., and Bolinao, J.G. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J. Cataract Refract. Surg. 33:63-68, 2007.
54. American Academy of Ophthalmology. Cataract in the adult eye, Preferred Practice Pattern. San Francisco: American Academy of Ophthalmology, 2006. Available at www.aao .org/ppp.